Short Interest in Alimera Sciences, Inc. (NASDAQ:ALIM) Decreases By 13.8%

Alimera Sciences, Inc. (NASDAQ:ALIM) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 578,500 shares, a decrease of 13.8% from the August 15th total of 670,900 shares. Based on an average daily volume of 846,400 shares, the days-to-cover ratio is presently 0.7 days.

Alimera Sciences Stock Performance

Shares of ALIM opened at $5.54 on Wednesday. The company’s fifty day simple moving average is $5.56 and its 200-day simple moving average is $4.40. The company has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta of 1.25. The company has a current ratio of 2.79, a quick ratio of 2.62 and a debt-to-equity ratio of 1.80. Alimera Sciences has a twelve month low of $2.61 and a twelve month high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The firm had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. As a group, analysts expect that Alimera Sciences will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Alimera Sciences

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Glazer Capital LLC bought a new position in Alimera Sciences in the 2nd quarter worth about $3,067,000. Ancora Advisors LLC bought a new position in Alimera Sciences in the 1st quarter worth about $915,000. Renaissance Technologies LLC increased its position in shares of Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after acquiring an additional 6,900 shares during the period. Finally, Deltec Asset Management LLC bought a new stake in shares of Alimera Sciences during the second quarter valued at approximately $690,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. HC Wainwright cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target on the stock. in a research note on Tuesday, June 25th. Maxim Group restated a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, StockNews.com assumed coverage on Alimera Sciences in a research report on Saturday. They issued a “hold” rating on the stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).